Shareholder Rights Law Firm Johnson Fistel, LLP, is investigating potential claims against Novartis AG (“Novartis”) (NYSE: NVS) for violations of federal securities laws.
|
SAN DIEGO, Aug. 7, 2019 /PRNewswire/ -- Shareholder Rights Law Firm Johnson Fistel, LLP, is investigating potential claims against Novartis AG ("Novartis") (NYSE: NVS) for violations of federal securities laws. On August 7, 2019, Novartis made known that it knew about discrepancies in data it submitted to regulators as it sought approval of its gene therapy drug Zolgensma, but delayed notifying authorities until it completed an internal investigation. Novartis faces possible penalties from the FDA. On August 6, 2019, the FDA said the company was aware of the problems for as much as two months before the drug's U.S. approval. If you recently purchased Novartis and lost money, realized or unrealized on your investment, and are interested in learning more about the investigation or your legal rights and remedies, please contact Jim Baker (jimb@johnsonfistel.com) by email or phone at 619-814-4471. If emailing, please include a phone number. Additionally, you can [click here to join this action]. There is no cost or obligation to you. About Johnson Fistel, LLP: Contact: [click here to join this action]
SOURCE Johnson Fistel, LLP |
||
Company Codes: NYSE:NVS |
View original content:
